Auner Lab

Contact


Dr Holger Auner

  • CRUK Advanced Clinician Scientist
  • Clinical Reader in Molecular Haemato-Oncology

+44 (0)20 3313 4017
holger.auner04@imperial.ac.uk

Areas of research


Proteotoxic stress and metabolism

Myeloma cells are characterised by a unique sensitivity to inhibitors of the proteasome, which is responsible for the controlled degradation of most cellular proteins that have become damaged or are otherwise unwanted. Nevertheless, resistance to proteasome inhibitors occurs in essentially all patients to varying degrees. Accumulation of misfolded proteins in the endoplasmic reticulum (ER), which triggers proteotoxic ‘ER stress’, is widely believed to be the main mechanism of action of proteasome inhibitors. However, data from our lab and other research groups suggest complex interactions between proteasomal protein degradation and multiple metabolic processes. Our aim is to find metabolic and proteostatic vulnerabilities that we can exploit therapeutically.


Tissue biophysics in myeloma biology

Several important aspects of cancer cell biology are influenced by mechanical cues from the surrounding tissue. In particular, mechanical interactions and matrix remodelling have been shown to govern cancer cell metabolism. Tissue stiffness also impacts on normal haematopoiesis, and mechanical cues are known to modulate therapeutic responses. Moreover, we have shown that proteostasis-targeting drugs can alter tissue physical properties. We aim to understand how tissue stiffness and nutrient availability act together to rewire metabolic networks and regulate drug responses in myeloma.


Citation

BibTex format

@article{Caputo:2021:10.1016/j.isci.2020.101989,
author = {Caputo, VS and Trasanidis, N and Xiao, X and Robinson, ME and Katsarou, A and Ponnusamy, K and Prinjha, RK and Smithers, N and Chaidos, A and Auner, HW and Karadimitris, A},
doi = {10.1016/j.isci.2020.101989},
journal = {iScience},
pages = {1--31},
title = {Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation in vitro},
url = {http://dx.doi.org/10.1016/j.isci.2020.101989},
volume = {24},
year = {2021}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Osteoclast development in response to RANKL is critical for bone homeostasis in health and in disease. The early and direct chromatin regulatory changes imparted by the BET chromatin readers Brd2-4 and osteoclast-affiliated transcription factors (TF) during osteoclastogenesis are not known. Here, we demonstrate that in response to RANKL, early osteoclast development entails regulation of two alternative cell fate transcriptional programmes, osteoclast vs macrophage, with repression of the latter following activation of the former. Both programmes are regulated in a non-redundant manner by increased chromatin binding of Brd2 at promoters and of Brd4 at enhancers/super-enhancers. Myc, the top RANKL-induced TF, regulates osteoclast development in co-operation with Brd2/4 and Max and by establishing negative and positive regulatory loops with other lineage-affiliated TF. These insights into the transcriptional regulation of osteoclastogenesis suggest the clinical potential of selective targeting of Brd2/4 to abrogate pathological OC activation.
AU - Caputo,VS
AU - Trasanidis,N
AU - Xiao,X
AU - Robinson,ME
AU - Katsarou,A
AU - Ponnusamy,K
AU - Prinjha,RK
AU - Smithers,N
AU - Chaidos,A
AU - Auner,HW
AU - Karadimitris,A
DO - 10.1016/j.isci.2020.101989
EP - 31
PY - 2021///
SN - 2589-0042
SP - 1
TI - Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation in vitro
T2 - iScience
UR - http://dx.doi.org/10.1016/j.isci.2020.101989
UR - https://www.sciencedirect.com/science/article/pii/S258900422031186X?via%3Dihub
UR - http://hdl.handle.net/10044/1/85254
VL - 24
ER -

Hugh and Josseline Langmuir Myeloma Centre